Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2026-06-17 18:38:53 ET · period of report 2026-06-15 · accession 0001610717-26-000229 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 18:38 | 2026-06-15 | CTMX | Ogden Christopher | CFO | S - Sale | $3.05 | -1,624 | 295.3K | -0.5% | -$4,953 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-15 | S | D | 1,624 | $3.05 | 295,324 | D | — | — | (F1) The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). (F2) Includes 167,249 RSUs. |